Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells

por Stefka, A T, Park, J-H, Matsuo, Y, Chung, S, Nakamura, Y, Jakubowiak, A J, Rosebeck, S
Publicado 2016

P847: MRD BY MASS SPECTROMETRY IN PERIPHERAL BLOOD AND NEXT GENERATION SEQUENCING IN BONE MARROW IN A PHASE 2 STUDY OF DARATUMUMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE FOR...

por Derman, B., Rosenblatt, J., Avigan, D., Major, A., Rampurwala, M., Barnidge, D., Stefka, A., Jiang, K., Jakubowiak, A.
Publicado 2022